Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc

Proceedings of the National Academy of Sciences of the United States of America
Gianluca MoronciniR Anthony Williamson

Abstract

Prion diseases are closely associated with the conversion of the cellular prion protein (PrPC) to an abnormal conformer (PrPSc) [Prusiner, S. B. (1998) Proc. Natl. Acad. Sci. USA 95, 13363-13383]. Monoclonal antibodies that bind epitopes comprising residues 96-104 and 133-158 of PrPC potently inhibit this process, presumably by preventing heterodimeric association of PrPC and PrPSc, and suggest that these regions of PrPC may be critical components of the PrPC-PrPSc replicative interface. We reasoned that transplanting PrP sequence corresponding to these regions into a suitable carrier molecule, such as an antibody, could impart specific recognition of disease-associated forms of PrP. To test this hypothesis, polypeptides containing PrP sequence between residues 89-112 or 136-158 were used to replace the extended heavy chain complementarity-determining region 3 of an IgG antibody specific for the envelope glycoprotein of HIV-1. Herein the resulting engineered PrP-IgGs are shown to bind specifically to infective fractions of PrP in mouse, human, and hamster prion-infected tissues, but not to PrPC, other cellular components, or the HIV-1 envelope. PrPSc reactivity was abolished when the sequence of the PrP 89-112 and 136-158 graft...Continue Reading

References

May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·K E McLaneP Ghazal
Sep 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·K KanekoS B Prusiner
Oct 23, 1997·Nature·A F HillP Lantos
May 28, 1998·The Journal of Biological Chemistry·J ChabryB Chesebro
Oct 10, 1998·Journal of Virology·R A WilliamsonD R Burton
Nov 13, 1998·Proceedings of the National Academy of Sciences of the United States of America·S B Prusiner
Dec 2, 2000·Nature·M B FischerA Aguzzi
Mar 7, 2001·Nature Medicine·A Aguzzi
Apr 11, 2001·Trends in Biochemical Sciences·B Caughey
Jul 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·M EnariC Weissmann
Jul 2, 2002·Journal of Neurochemistry·Yuval ShakedRuth Gabizon
Jun 5, 2003·Nature Medicine·Eustache ParamithiotisNeil R Cashman

❮ Previous
Next ❯

Citations

Feb 19, 2008·Archives of Virology·Estelle Leclerc, Stefan Vetter
Sep 10, 2005·Nature Biotechnology·Philipp Holliger, Peter J Hudson
Dec 16, 2011·Proceedings of the National Academy of Sciences of the United States of America·Joseph M PerchiaccaPeter M Tessier
Feb 24, 2010·The Journal of Biological Chemistry·Yuko Ushiki-KakuTakashi Yokoyama
Oct 18, 2007·The Journal of Biological Chemistry·James C GeogheganSurachai Supattapone
Oct 2, 2008·The Journal of Biological Chemistry·Gil C AbalosLaura Solforosi
Oct 28, 2011·The Veterinary Quarterly·Alan RigterAlex Bossers
Oct 7, 2006·Nucleic Acids Research·Csaba KissAndrew R M Bradbury
Jul 16, 2009·Protein Engineering, Design & Selection : PEDS·Li LiNeil R Cashman
Jan 14, 2011·Journal of Virology·Michael B Miller, Surachai Supattapone
Dec 1, 2009·BMC Biochemistry·Alan RigterAlex Bossers
Apr 14, 2007·BMC Biochemistry·Alan RigterAlex Bossers
Mar 21, 2009·BMC Immunology·Anja Colja VenturiniVladka Curin Serbec
Aug 1, 2012·PloS One·Binggong ChangRichard Rubenstein
Apr 13, 2006·PLoS Pathogens·Joel C WattsDavid Westaway
Jul 23, 2011·PLoS Pathogens·Michael B MillerSurachai Supattapone
Jun 30, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jessie A TurnbaughDavid A Harris
Oct 1, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Christina J SigurdsonAdriano Aguzzi
Jan 25, 2008·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Andreas Müller-Schiffmann, Carsten Korth
Dec 18, 2013·Biochemistry·Ashley A ZurawelSurachai Supattapone
Jul 20, 2006·Proceedings of the National Academy of Sciences of the United States of America·Jiri G SafarStanley B Prusiner
Jul 3, 2007·Proceedings of the National Academy of Sciences of the United States of America·Anthony L LauDavid Peretz
Apr 28, 2009·Cellular and Molecular Life Sciences : CMLS·Sabine Gilch, Hermann M Schätzl
Aug 7, 2007·Expert Review of Anti-infective Therapy·Heike LudewigsStefan Weiss
Mar 21, 2006·FEBS Letters·Jan ZieglerStephan Schwarzinger
Feb 1, 2008·Expert Opinion on Medical Diagnostics·Alexander H PedenJames Ironside
Feb 16, 2005·Expert Opinion on Biological Therapy·Jennifer K Griffin, Neil R Cashman
Sep 2, 2009·Journal of Molecular Biology·Maurizio PolanoGiuseppe Legname
Nov 4, 2008·Journal of Neuroimmunology·Binggong ChangRichard Rubenstein
Aug 15, 2015·Annual Review of Biomedical Engineering·Kathryn E Tiller, Peter M Tessier
Mar 15, 2008·Journal of Virological Methods·Luisa GregoriRobert G Rohwer
Jun 19, 2007·Journal of Molecular Biology·Sabine GilchHermann M Schätzl
Feb 10, 2007·The FEBS Journal·Ilia V Baskakov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bovine Spongiform Encephalopathy (MDS)

Bovine spongiform encephalopathy is a neurodegenerative disease belonging to the transmissible spongiform encephalopathies, a group of diseases including sheep scrapie and human Creutzfeldt-Jakob disease. Here is the latest research.

Bovine Spongiform Encephalopathy

Bovine spongiform encephalopathy is a neurodegenerative disease belonging to the transmissible spongiform encephalopathies, a group of diseases including sheep scrapie and human Creutzfeldt-Jakob disease. Here is the latest research.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.